Mikhail Blagosklonny is a research scientist focusing on the study cancer and aging. He is also an instructor teaching oncology at the Roswell Park Cancer Institute. He is also a philanthropist. In the scientific community, he works as editor-in-chief for several publications such as Oncotarget, Aging, and Cell Cycle. Mikhail Blagosklonny studied at the First Pavlov State Medical University of St. Peterburg, where he earned a Master’s degree in internal medicine as well as a Ph.D. in experimental medicine. In 2002, he was employed as an assistant professor of medicine at New York Medical College in Valhalla. He later served as a senior scientist at Ordway Research Institute in Albany, New York.
Mikhail Blagosklonny is interested in cancer and cancer therapies that protect normal cells from damage research. He also specializes in the mechanism of aging and anti-aging drugs. He is one of the dedicated doctors who are very skilled in areas of oncology and hematology. He is well-known in carrying various clinical experiments in order to come up with a better treatment of cancer to patients. Mikhail and his devoted team of oncologists and hematologists offer specialized care to their patients. They are at all-time ready to offer treatment at The Roswell Park Cancer Institute. They give personalized treatments owing that patients have different genetic makeups and patients are affected differently by cancer.
Mikhail Blagosklonny is well recognized through one of his discoveries of Rapamycin. Rapamycin is a drug with implausible healing properties. The drug is used to prevent tissue rejection after transplanting an organ successfully. According to Mikhail, the drug is also convenient in hemolytic-uremic syndrome treatment. This is because the drug not only reduces the level of toxicity after a kidney transplant but also prevents rejection of the new organ. Mikhail also claims that the drug has other benefits in the general human body apart from fighting cancer. The drug can effectively treat Lymphangioleiomyomatosis as well as tuberous sclerosis complex which affects several acute organs like the brain, kidney, and the heart.
Mikhail Blagosklonny also believes that Rapamycin contains a property that can prolong a person’s life. He has done experiments on mice that show promising results even though tests on humans are yet to be done. He also says that the drug can be used to treat muscular dystrophy, which is weakening of muscles. He has shown this through mice tests that showed a development of strength by over 30%. Although research is going on, he has self-confidence that the drug can be used to correct mental effects and be used to prevent and treat Alzheimer disease.
Mikhail Blagosklonny continues to undertake research that will continue being of importance within the oncology field. He has been a role model to his peers and students who want to be part of the team that will advance his research in future. He has made a big progress in the field and his hope is that this has inspired many individuals who will pick up and continue with the research after him. He is focused on making sure that the treatment of cancer will be easy and a cost affordable treatment in future.